Physician profile
Ali Bazzi
NPI 1386094464
$4,443.95
in general payments reported to CMS, 2019-2025
11 companies · $2,381 in 2025
The $2,381 reported for 2025 was more than what 94% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $57.01 · 2021: $307 · 2022: $102 · 2023: $1,392 · 2024: $84.25 · 2025: $2,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,631 · Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,630.56 |
| Food and Beverage | $1,226.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,181.73 | 2021-2025 | Truclear, Cobalt Dr Mri Surescan, Abre |
| Ferring Pharmaceuticals INC. | $1,468.87 | 2020-2025 | Menopur |
| Hologic Sales and Service, LLC | $169.30 | 2025 | Acessa Provu System, Myosure Tissue Removal Device |
| Coopersurgical, INC. | $164.65 | 2025 | Origio Sequential Fert |
| Astrazeneca Pharmaceuticals LP | $120.75 | 2019 | |
| Abbvie INC. | $102.70 | 2021-2025 | |
| Emd Serono, INC. | $97.91 | 2021-2025 | |
| Novo Nordisk INC | $72.24 | 2023-2025 | Wegovy |
| Organon LLC | $32.67 | 2025 | Pregnyl, Follistim Aq, Ganirelix Acetate |
| Allergan, INC. | $17.49 | 2020 | |
| Merck Sharp & Dohme LLC | $15.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Bazzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.